The Sabin Vaccine Institute has launched a “multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate.”
Participants in Melbourne, Florida, will be the first to receive doses.
“This trial builds on ongoing Phase 2 testing in Kenya and Uganda, with initial findings from that research expected in the coming months,” Sabin Vaccine Institute wrote.
Remember about four years ago when I told you all that they were going to roll out "Marburg" virus (lab-created version) within the next couple years, and that the "vaccine" was already in production? We Conspiracy Theorists don't WANT to be right…… we just are. pic.twitter.com/eOYw6wfCt8
— Aeron (@FYourVaccines) April 26, 2025
From The Sabin Vaccine Institute:
Sabin’s vaccine development efforts, including clinical trials, are becoming increasingly critical as Marburg outbreaks grow in frequency, underscoring the urgent need for vaccines to protect those at highest risk. Sabin supported an open-label Phase 2 clinical trial sponsored by the Rwanda Biomedical Centre (RBC) by supplying the investigational vaccine during Rwanda’s 2024 Marburg outbreak. More than 1,700 individuals — primarily frontline health care workers — were vaccinated, with first doses arriving within nine days of the outbreak being declared. Data from the RBC trial will be shared with Sabin to support the vaccine’s licensure.
Rwanda’s outbreak ended on December 20 with a case fatality rate of 23%, lower than the historical average of 50%. Fatality rates in outbreaks can vary due to multiple factors, including greater surveillance, prompt detection, supportive care, and the overall response effort. On January 20, Tanzania declared an outbreak of Marburg virus disease, which ended on March 13.
Currently, there are no approved vaccines for Marburg virus disease.
For the U.S. clinical trial that began this week, Sabin will recruit 200 volunteers aged 18 to 70 across four locations – in addition to Melbourne, the vaccine will be tested at sites in Dallas, Texas; Huntsville, Alabama; and Peoria, Illinois. The randomized, placebo-controlled, double-blind trial will continue to evaluate safety and immunogenicity, and monitor vaccinated volunteers for a year.
“Recent outbreaks highlight the urgent need to strengthen our defenses against this deadly and unforgiving disease,” Amy Finan, Sabin’s Chief Executive Officer, said.
“Sabin’s Phase 2 clinical trials will generate essential data to move this vaccine closer to licensure — and offer a potentially life-saving tool where none exists,” Finan added.
What could go wrong?
The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the first participants in Melbourne, Florida. This trial builds on ongoing Phase 2 testing in Kenya and Uganda,… pic.twitter.com/bkzPLcLu2y
— Informed NJ Nurses (@InformedNJNurse) April 26, 2025
There are currently no approved vaccines for the Marburg virus disease, a virulent condition leading to haemorrhagic fever.
The disease is caused by the Marburg filovirus, which belongs to the Ebola virus family.
Sabin’s investigational vaccine is based on GSK’s Chimpanzee Adenovirus Type 3 (cAd3) platform and has shown promise in Phase I clinical and non-clinical trials, demonstrating safety and the ability to cause quick immune responses.
Sabin is developing the vaccine amid more frequent outbreaks of the Marburg virus disease, highlighting the need for vaccines to protect high-risk populations.
During Rwanda’s Marburg outbreak last year, the institute contributed to an open-label Phase II trial by supplying the vaccine, which was administered to more than 1,700 subjects within nine days of the outbreak being declared.
Rwanda Biomedical Centre (RBC) offered support for this open-label trial, the data from which will play a key role in supporting the vaccine’s licensure process.
Source link